Experimental cancer treatments

Turnstone Biologics Raises $80 Million Series D Financing

Retrieved on:

Wednesday, July 21, 2021

Oncology, Health, Other Science, Clinical trials, Science, Pharmaceutical, Biotechnology, Virotherapy, Oncolytic virus, Turnstone, Immunotherapy, Experimental cancer treatments, Branches of biology

Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, today announced the successful completion of an $80 million Series D financing co-led by PFM Health Sciences and Point72.

Key Points:

Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, today announced the successful completion of an $80 million Series D financing co-led by PFM Health Sciences and Point72.
Turnstone is developing next-generation medicines in two of the most clinically validated fields of immunotherapy for solid tumors, said Sammy Farah, Ph.D., MBA, President and CEO at Turnstone.
This oversubscribed financing will allow us to advance our vision to benefit millions of cancer patients underserved by current treatment options.
Proceeds from the financing will be used to advance Turnstones pipeline of programs from its oncolytic virus and TIL therapy platforms.

Replimune to Present at the William Blair Biotech Focus Conference 2021

Retrieved on:

Wednesday, July 7, 2021

Oncolytic virus, Experimental cancer treatments, Biotechnology, Virotherapy

WOBURN, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that Robert Coffin, Ph.D., President and Chief Research & Development Officer of Replimune, will participate in a panel titled Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumors at the William Blair Biotech Focus Conference 2021 taking place virtually on Wednesday, July 14, 2021 at 4:20 PM ET.

Key Points:

WOBURN, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced that Robert Coffin, Ph.D., President and Chief Research & Development Officer of Replimune, will participate in a panel titled Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumors at the William Blair Biotech Focus Conference 2021 taking place virtually on Wednesday, July 14, 2021 at 4:20 PM ET.
A simultaneous webcast will be available in the Investors section of Replimunes website at www.replimune.com.
A replay will be available for approximately 90 days following the conference.
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer.

TILT Biotherapeutics Submits IND for Phase I Trial of Immunotherapeutic TILT-123 in Ovarian Cancer

Retrieved on:

Monday, June 14, 2021

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Cancer treatments, Clinical medicine, Medicine, Virotherapy, Biotechnology, Experimental cancer treatments, Cancer immunotherapy, Adenoviridae, Pembrolizumab, Oncolytic adenovirus, Oncolytic virus, Akseli Hemminki

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, today announces that it has submitted an IND for its Phase I trial of immunotherapeutic TILT-123 in ovarian cancer.

Key Points:

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, today announces that it has submitted an IND for its Phase I trial of immunotherapeutic TILT-123 in ovarian cancer.
The trial will evaluate the companys adenoviral cancer immunotherapy TILT-123, a double cytokine armed oncolytic adenovirus, in combination with KEYTRUDA (pembrolizumab), MSDs anti-PD-1 therapy, in a dose escalation trial in platinum resistant or refractory ovarian cancer patients.
During the first month of the trial, patients will receive TILT-123 monotherapy, and thereafter TILT-123 in conjunction with pembrolizumab.
TILT Biotherapeutics also announces changes to the board of directors, with Jyrki Liljeroos, formerly a board advisor, appointed as Chairman.

Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)

Retrieved on:

Tuesday, June 8, 2021

Oncology, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Virotherapy, Medicine, Life sciences, Gene delivery, Experimental cancer treatments, Oncolytic virus, Biotechnology, Virus, Vector, Viral vector, Pexastimogene devacirepvec

Candidates based on this viral design aim to stimulate an immune response locally in the tumor and to optimize the safety profile of the virus.

Key Points:

Candidates based on this viral design aim to stimulate an immune response locally in the tumor and to optimize the safety profile of the virus.
Transgene has already obtained patent grants for this new technology in the US, Europe, Australia, Hong Kong, Israel, and Russia.
By protecting the vectorization of ICIs in our VVcopTK-RR- oncolytic viruses, we are extending our Invir.IO IP beyond the original viral backbone protection.
With its proprietary platform Invir.IO, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.

Cybrexa Therapeutics Announces Publication of Peer-Reviewed Article in NAR Cancer

Retrieved on:

Tuesday, June 8, 2021

Oncology, Clinical medicine, Medicine, Cancer, Antineoplastic drugs, Biotechnology, Medical specialties, Experimental cancer treatments

The study, entitled Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity, appears in NAR Cancer, Volume 3, Issue 2, June 2021.

Key Points:

The study, entitled Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity, appears in NAR Cancer, Volume 3, Issue 2, June 2021.
The study found that CBX-12 displays pH selectivity, stability in plasma and selective delivery of exatecan to tumor cells versus healthy tissue.
These findings are a major boost as CBX-12 advances through its first clinical trial, and we work toward making effective therapeutics available to more patients.
Cybrexa is a privately-held biotechnology company dedicated to developing next-generation tumor-targeted cancer therapies using its alphalex platform.

Calidi Biotherapeutics Announces Partnership with GenScript ProBio for Distribution of its SuperNova-1 Technology

Retrieved on:

Tuesday, June 8, 2021

We look forward to seeing this partnership with GenScript ProBio increase distribution of our enhanced oncolytic virotherapy delivery technology for potential therapeutic treatments of multiple cancer indications.

Key Points:

We look forward to seeing this partnership with GenScript ProBio increase distribution of our enhanced oncolytic virotherapy delivery technology for potential therapeutic treatments of multiple cancer indications.
The SuperNova-1 product indicates exciting potential for the future of cancer treatment, said Brian Hosung Min, CEO of GenScript ProBio.
With our expertise in global sales and distribution organization, this partnership is well-poised to generate global growth around Calidis revolutionary technology.
GenScript ProBio will pay Calidi a low double-digit percentage of the net revenue produced by its SNV-1 manufacturing services per the agreement reached.

IconOVir Bio to Present at Jefferies Healthcare Conference

Retrieved on:

Thursday, May 27, 2021

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Experimental cancer treatments, Medicine, Clinical medicine, Virotherapy, Health sciences, Biotechnology, Oncolytic virus, Virus, Akseli Hemminki, Enadenotucirev

IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the Jefferies Healthcare Conference on Thursday, June 3, 2021 at 3:00 p.m.

Key Points:

IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the Jefferies Healthcare Conference on Thursday, June 3, 2021 at 3:00 p.m.
IconOVir is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer.
IconOVirs proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh OShea, Ph.D., of the Salk Institute.
It is designed to address key limitations of first- and second-generation oncolytic viruses and provide a personalized therapy for cancer patients.

Transgene and BioInvent Receive IND Approval from the U.S. FDA for BT-001, a Novel Oncolytic Virus for the Treatment of Solid Tumors

Retrieved on:

Thursday, May 27, 2021

Biotechnology, FDA, Health, Pharmaceutical, Oncology, Virotherapy, Experimental cancer treatments, Biotechnology, Medicine, Oncolytic virus, Life sciences, Health care, Transgene SA, Pexastimogene devacirepvec

This IND will allow patients in the U.S. to be enrolled into the ongoing Phase I/IIa clinical trial of this novel oncolytic virus BT-001.

Key Points:

This IND will allow patients in the U.S. to be enrolled into the ongoing Phase I/IIa clinical trial of this novel oncolytic virus BT-001.
Hedi Ben Brahim, Chairman and CEO of Transgene, said: We have designed BT-001 to significantly improve treatment for patients with solid tumors by restoring their immune response against cancer.
We are pleased to receive IND approval for this Phase I/IIa clinical trial of BT-001, which is BioInvents fourth clinical program.
The scientific and clinical development of the oncolytic virus candidate BT-001 is a 50/50 collaboration between BioInvent and Transgene.

BioInvent and Transgene receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors

Retrieved on:

Thursday, May 27, 2021

Experimental cancer treatments, Virotherapy, T cells, Branches of biology, Medicine, Clinical medicine, Biotechnology, Oncolytic virus, CTLA-4, Regulatory T cell, Pexastimogene devacirepvec, Enadenotucirev

This IND will allow patients in the U.S. to be enrolled into the ongoing Phase 1/2a clinical trial of this novel oncolytic virus BT-001.

Key Points:

This IND will allow patients in the U.S. to be enrolled into the ongoing Phase 1/2a clinical trial of this novel oncolytic virus BT-001.
In addition, delivering the anti-CTLA4 antibody directly to the tumor aims to induce local Treg depletion and strong therapeutic activity.
"We are pleased to receive IND approval for this Phase 1/2a clinical trial of BT-001, which is BioInvent's fourth clinical program.
The scientific and clinical development of the oncolytic virus candidate BT-001 is a 50/50 collaboration between BioInvent and Transgene.

BioInvent and Transgene receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors

Retrieved on:

Thursday, May 27, 2021

This IND will allow patients in the U.S. to be enrolled into the ongoing Phase 1/2a clinical trial of this novel oncolytic virus BT-001.

Key Points:

This IND will allow patients in the U.S. to be enrolled into the ongoing Phase 1/2a clinical trial of this novel oncolytic virus BT-001.
In addition, delivering the anti-CTLA4 antibody directly to the tumor aims to induce local Treg depletion and strong therapeutic activity.
"We are pleased to receive IND approval for this Phase 1/2a clinical trial of BT-001, which is BioInvent's fourth clinical program.
The scientific and clinical development of the oncolytic virus candidate BT-001 is a 50/50 collaboration between BioInvent and Transgene.